|
endometrial adenoacanthoma
|
0.200 |
Biomarker
|
disease |
RGD |
Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping.
|
15942940 |
2005 |
|
Endometrial adenocarcinoma
|
0.200 |
Biomarker
|
disease |
RGD |
Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping.
|
15942940 |
2005 |
|
Endometrial Endometrioid Adenocarcinoma
|
0.200 |
Biomarker
|
disease |
RGD |
Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping.
|
15942940 |
2005 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our result showed that a vector containing the PRC1 or RRM2 promoter could be used for breast cancer specific overexpression in gene therapy.
|
18587273 |
2008 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
A total of 28 different expression genes were hub genes, wherein AMPD1 and RRM2 were significantly effective in the prediction of survival of BC patients, with 0.04 and 0.02, respectively.
|
30556899 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
DSCAM-AS1/miR-204-5p/RRM2 may serve as novel therapeutic targets for BC.
|
30457164 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our study suggests for evaluating RRM2-associated metabolites as noninvasive markers for tamoxifen resistance and its pharmacological inhibition as a novel approach to overcome tamoxifen resistance in BCa.
|
25016594 |
2014 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
RRM2 gene expression decreases in metastases when compared to primary breast cancer and could be suggested as a marker to trace breast cancer evolution.
|
28782484 |
2017 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
We found out that NEAT1/miR-21/RRM2 axis may play a role in BC diagnosis and prognosis.
|
31621912 |
2020 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine the prognostic value of breast cancer susceptibility gene 1 (BRCA1), excision repair cross-complementation 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), and ribonucleotide reductase subunit M2 (RRM2) in patients with advanced non-small cell lung cancer (NSCLC) who received platinum-based chemotherapy.
|
25227663 |
2014 |
|
Malignant neoplasm of breast
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Two variants in EIF3A (rs10787899 and rs3824830; P < 0.01) and four variants in SART1 (rs660118, rs679581, rs754532, and rs735942; P(trend) < or = 0.02) were significantly associated with an altered risk of breast cancer along with single variants in RRM2, PSCD3, C11orf51, CDC16, SNW1, MFAP1, and CDC2 (P < 0.05).
|
19377877 |
2010 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Further analysis indicated that RRM2 was a more accurate prognostic biomarker for ER-negative breast cancers than the pathoclinical indicators and uPA.
|
25213022 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
These results show promise for the use of RRM2 siRNA-based therapy for HNSCC and possibly NSCLC.
|
22342644 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Ribonucleotide reductase subunits M1 (RRM1) and M2 (RRM2) are involved in the metabolism of gemcitabine (2',2'-difluorodeoxycytidine), which is used for the treatment of nonsmall cell lung cancer.
|
18414411 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to investigate rs13181 ERCC2 (T>G) (Lys751Gln), rs12806698 RRM1 (-269C>A) and rs6759180 (located in the 5'UTR) RRM2 (10126436G>A) gene polymorphisms by using real time PCR technique in patients with NSCLC.
|
26718430 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Knockdown of RRM2 led to apoptosis through the intrinsic pathway in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cell lines.
|
23719266 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of RRM2, LINC0066 and miR-143-3p in NSCLC tumor tissues and cell lines were detected using qRT-PCR.
|
31819489 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
|
25227663 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, AFAP1-AS1 enhanced NSCLC cell proliferation and chemotherapy resistance through upregulation of RRM2 by inhibiting miR-139-5p expression.
|
31696057 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus docetaxel in advanced non-small-cell lung cancer (NSCLC) patients.
|
19002265 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The NSCLC microarray dataset showed RRM2 and TS as biomarkers significantly associated with OS.
|
26663950 |
2015 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We found out that NEAT1/miR-21/RRM2 axis may play a role in BC diagnosis and prognosis.
|
31621912 |
2020 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
DSCAM-AS1/miR-204-5p/RRM2 may serve as novel therapeutic targets for BC.
|
30457164 |
2019 |
|
Breast Carcinoma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Two variants in EIF3A (rs10787899 and rs3824830; P < 0.01) and four variants in SART1 (rs660118, rs679581, rs754532, and rs735942; P(trend) < or = 0.02) were significantly associated with an altered risk of breast cancer along with single variants in RRM2, PSCD3, C11orf51, CDC16, SNW1, MFAP1, and CDC2 (P < 0.05).
|
19377877 |
2010 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
RRM2 gene expression decreases in metastases when compared to primary breast cancer and could be suggested as a marker to trace breast cancer evolution.
|
28782484 |
2017 |